Achieve Life Sciences Announces Initiation of ORCA-OL Clinical Trial Evaluating Long-Term Exposure of Cytisinicline in People who Smoke or Use Nicotine E-Cigarettes
Achieve Life Sciences, Inc. - Common Shares (ACHV)
Last achieve life sciences, inc. - common shares earnings: 3/13 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.achievelifesciences.com
Company Research
Source: GlobeNewswire
SEATTLE and VANCOUVER, British Columbia, May 29, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), or Achieve, a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced it has initiated screening of subjects for the open-label ORCA-OL clinical trial. The trial is expected to provide long-term cytisinicline safety exposure data from subjects who currently smoke or use nicotine e-cigarettes and is required for submission of the cytisinicline New Drug Application, or NDA, and ultimately potential approval and marketing authorization in the United States. ORCA-OL is designed to evaluate the long-term exposure of 3 mg cytisinicline treatment dosed three times daily in U.S. adults who want to quit smoking or vaping. Recruitment to the study is focused on engaging prior ORCA Phase 2 or Phase 3 trial participants, who have relapsed or continued to smoke or
Show less
Read more
Impact Snapshot
Event Time:
ACHV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACHV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACHV alerts
High impacting Achieve Life Sciences, Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
ACHV
News
- Achieve Life Sciences Announces Changes in Executive Leadership and Board of Directors [Yahoo! Finance]Yahoo! Finance
- Achieve Life Sciences Announces Changes in Executive Leadership and Board of Directors [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Achieve Life Sciences Announces Changes in Executive Leadership and Board of DirectorsGlobeNewswire
- Achieve Life Sciences, Inc. (NASDAQ: ACHV) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $11.00 price target on the stock.MarketBeat
- Achieve Life Sciences, Inc. (ACHV) Q2 2024 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
ACHV
Earnings
- 8/13/24 - Miss
ACHV
Sec Filings
- 8/26/24 - Form 8-K
- 8/20/24 - Form 4
- 8/20/24 - Form 4
- ACHV's page on the SEC website